Trial Profile
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs ALRN 6924 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; CNS cancer; Hepatoblastoma; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Retinoblastoma; Rhabdoid tumour; Solid tumours; Teratoma
- Focus Adverse reactions
- 16 Aug 2023 Status changed from discontinued to completed.
- 20 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
- 20 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.